PRECISIONBIOLOGICS
Menu
↗
PRECISION BIOLOGICS / LOCATIONS

Aesthetic Practice Biologics Supplier in Birmingham, Alabama

Precision Biologics is a master distributor supplying Wharton's jelly allograft products and extracellular vesicle products to licensed dermatology, plastic surgery and medical spa practices operating under physician supervision. Aesthetic practices in Birmingham, Alabama use this page to understand account verification, documentation and shipping before placing a first order. Precision Biologics sells only to licensed professionals and does not describe any product's effect on skin appearance or any other outcome.

REGISTRY DATA / AL

Birmingham

NPPES registry listings, primary taxonomy, retrieved 2026-10-27

121
Dermatology
90
Plastic Surgery
31
Source: NPPES NPI Registry ↗

Who Holds the Account at a Medspa Versus a Physician Practice

A dermatology or plastic surgery practice that is itself physician-owned can typically apply for a Precision Biologics account directly under the treating physician's own National Provider Identifier.

A medical spa that is not a physician practice generally needs its supervising or medical director physician to hold the account instead, since every account is verified against NPPES by NPI.

Shipping Formats and What They Mean for a New Aesthetic Account

Practices new to carrying these products often start with a lyophilized format such as Bio DPM, Bio EX or Bio AER, since these are shelf-stable under normal storage and do not require the ultra-low freezer capacity that cryopreserved formats need.

Cryopreserved Wharton's jelly formats ship overnight on dry ice and require prompt transfer to -80 degree Celsius storage on arrival; in the Southeast, summer ambient heat shortens the window before a dry-ice shipment should be brought inside.

Documentation Available to Verified Birmingham Accounts

Verified accounts can request a certificate of analysis, donor eligibility summary and, for exosome products, the supplier's reported characterization data and growth-factor and cytokine panel, presented as analytical findings rather than claims about effect.

Full ingredient disclosure for lyophilized exosome products is also provided to verified accounts rather than published on this site.

Verifying Licensure Before Ordering

Precision Biologics asks every Birmingham aesthetic practice to confirm its own licensure and, where applicable, supervising-physician arrangement with the Medical Licensure Commission of Alabama and relevant allied-health boards, and to review scope-of-practice and regulatory classification questions with practice counsel.

Precision Biologics' role is limited to NPI verification, supplying requested documentation and arranging a physician-level call about that documentation, not clinical or scope-of-practice advice.

FDA has stated there are no FDA-approved exosome products. Exosome products are generally regulated as biologic drugs under section 351 of the Public Health Service Act, not as 361 HCT/Ps. Purchase and clinical use decisions belong to the physician with their own regulatory counsel.

These products are not FDA approved or licensed for any disease or condition. Information is for licensed healthcare professionals and is not medical or legal advice.

FAQ

Frequently asked questions

Does a Birmingham medical spa need its own NPI to open an account?+

The business itself does not need an NPI, but the supervising or medical director physician does, and that physician's NPI is what Precision Biologics verifies against NPPES before approving the account.

Are these products labeled as stem cell products for aesthetic use?+

No. Commercial cord tissue allografts of this kind are not documented to contain viable stem cells, and Precision Biologics does not market them as stem cell therapy or describe any effect on skin appearance.

What should a Birmingham dermatology or plastic surgery practice review before adding inventory?+

Confirm licensure with the Medical Licensure Commission of Alabama, and have practice counsel assess the intended use against 21 CFR 1271.10 and, for exosome products, section 351 biologic drug regulation.